![]() ![]() Patients and healthcare professionals are asked to report any suspected adverse reactions to State Agency of Medicines. This medicinal product is subject to additional monitoring. Xofigo® Radioactive Therapeutic Agent Medicare Advantage Policy Guideline Author: UnitedHealthcare Subject: This policy addresses the use of Xofigo® (radium Ra 223 dichloride) injection for the treatment of castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no known visceral metastatic disease. La sécurité demploi et lefficacité du Xofigo nont pas été étudiées au-delà de 6 injections. Les injections sont répétées à intervalle de 4 semaines jusquà un maximum de 6 injections. Xofigo et chez 0,33 des patients (1/301) du groupe placebo. Summary of product characteristics (SPC): La posologie de Xofigo correspond à une activité de 55 kBq par kg de masse corporelle. Solution (Composition pour 1 ml de solution) > radium (223Ra) 0,58 ng à la date de référence. dONM ont été rapportés chez 0,67 des patients (4/600) du groupe. ![]() Xofigo monotherapy or in combination with luteinising hormone releasing hormone (LHRH) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC), symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines of systemic therapy for mCRPC (other than LHRH analogues), or ineligible for any available systemic mCRPC treatment (see section 4.4). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |